Introducing The BioCentury Show, plus Califf, COVID and GSK 

BioCentury’s new in-depth conversational series launches with Scott Gottlieb as debut guest 

On the latest BioCentury This Week podcast, senior editors preview The BioCentury Show, a biweekly in-depth conversation with some of the most important and interesting people in life sciences that launches this week. The open access 30-minute program, which will be hosted by Editor in Chief Simone Fishburn and Washington Editor Steve Usdin, debuts with former FDA Commissioner Scott Gottlieb, and will feature in the coming weeks key players globally from pharma, biotech, finance, market access, academia and non-profit organizations.

The editors also discuss the latest from Washington, where Robert Califf’s nomination awaits a vote by the full Senate and the White House wrestles to rework its COVID strategy. They also look at the pipeline Tony Wood will inherit at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) when he takes over the CSO role from Hal Barron, and spotlight emerging companies 64-X Inc., which is a Harvard spinout that aims to break bottlenecks in viral vector manufacturing; CAR T therapy developer ImmPACT Bio USA Inc.; RA Capital-incubated protein degradation play Avilar Therapeutics Inc.; and Ceptur Therapeutics Inc., an RNA oligonucleotide company.  

Sponsorship and underwriting packages are available for BioCentury’s webinars, podcasts and surveys. For more information, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.